Introduction
Methods
Inclusion criteria |
Phase II or phase III |
Placebo-controlled |
Conducted between 1995 and 2022 |
Results available on ClinicalTrials.gov or in a peer-reviewed publication |
Include patients meeting MCI or mild-to-moderate AD criteria (early AD, mild AD dementia, and mild-to-moderate AD dementia trials) |
Exclusion criteria |
Terminated before completion |
Primary outcome measures that could add heterogeneity to estimates (i.e., depression, sleep disturbance, agitation, psychosis, apathy) |
Primary outcome measure of time to conversion |
Randomized withdrawal trials |
Crossover design trials |
Trials enrolling participants with different types of dementia (i.e., mixed dementia, vascular dementia) |
Open-label trials |
Primary objective to assess the uptake, safety, reliability, or accuracy of positron emission tomography (PET) scans (or PET tracers) |